drugset / Trial / NCT03674242
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, randomized, Phase 2/3 study in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC) with no more than one prior systemic therapy for locally recurrent or metastatic disease.
Timeline
- Start
- 2019-06-13
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRASPA | Protein / enzyme biologic | 100 iu/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |